Drug Trial Radar · NCT03439670
A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Last checked: Nov 19, 2026Latest source record: Mar 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
Jun 29, 2018
Primary completion
Feb 23, 2021
Study completion Aug 19, 2021
Sponsor
- Lead sponsor
- ReveraGen BioPharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- European Union; Cooperative International Neuromuscular Research Group; Newcastle University; University of Pittsburgh
- First posted
- Feb 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Brief Summary: This Phase IIb study is a randomized, double-blind, parallel group, placebo and active-controlled study to evaluate the efficacy, safety, PD, and population PK of vamorolone administered orally at daily doses of 2.0 mg/kg and 6.0 mg/kg versus prednisone 0.75 mg/kg/day and placebo over a Treatment Period of 24 weeks, and to evaluate persistence of effect over a Treatment Period of 48 weeks in ambulant boys ages 4 to \<7 years with DMD.
Conditions
- Duchenne Muscular Dystrophy
Interventions
VamoroloneDrug
Oral administration of 2.0 mg/kg/day for the duration of the study.
PrednisoneDrug
Oral administration of 0.75 mg/kg/day for 24 weeks.
PlaceboOther
Oral administration of placebo daily for 24 weeks.
VamoroloneDrug
Oral administration of 6.0 mg/kg/day for the duration of the study.
PrednisoneDrug
Oral administration of 0.75 mg/kg/day for 24 weeks.
PlaceboOther
Oral administration of placebo daily for 24 weeks.
VamoroloneDrug
Oral administration of 2.0 mg/kg/day for 20 weeks.
VamoroloneDrug
Oral administration of 6.0 mg/kg/day for 20 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Measured by Time to Stand Test (TTSTAND) Velocity in Rises/Second Change From BaselineTime frame: 24 weeks
Locations
33 sites in 11 countries. Site status is shown where the registry gives one.
University of California Davis
Davis, California
University of California Los Angeles
Los Angeles, California
Children's Hospital Colorado
Aurora, Colorado
Nemours Children's Hospital
Orlando, Florida
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois
Gillette Children's Speciality Health Care
Saint Paul, Minnesota
Duke Children's Hospital
Durham, North Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
Children's Hospital of Virginia of Virginia Commonwealth University
Richmond, Virginia
Seattle Children's Hospital
Seattle, Washington
Royal Children's Hospital
Melbourne, Australia
Sydney Children's Hospital
Westmead, Australia
Ghent University Hospital
Ghent, Belgium
University Hospitals Leuven
Leuven, Belgium
Alberta's Children Hospital
Calgary, Alberta, Canada
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
Montreal Children's Hospital
Montreal, Quebec, Canada
University Hospital Brno
Brno, Czechia
Charles University
Prague, Czechia
Agia Sofia Children's Hospital
Athens, Greece
Schneider Children's Medical Center
Petah Tikvah, Israel
Leiden University Medical Center
Leiden, Netherlands
Radboud University
Nijmegen, Netherlands
Sant Joan de Deu Hospital - Barcelona, Spain
Barcelona, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Queen Silvia Children's Hospital
Gothenburg, Sweden
Birmingham Heartlands Hospital
Birmingham, United Kingdom
Royal Hospital for Children
Glasgow, United Kingdom
Leeds Teaching Hospital Trust
Leeds, United Kingdom
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom
Great Ormond Street Hospital
London, United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.